Dear Reviewer,

Thank you for your kind consideration for publication of our manuscript entitled “The synergistic anti-tumor activity of EZH2 inhibitor SHR2554 and HDAC inhibitor chidamide through ORC1 reduction of DNA replication process in diffuse large B cell lymphoma” in Cancers. We deeply appreciate your insightful comments and helpful suggestions. We have made revisions accordingly and responded all the comments point-by-point as follows.

1. In the abstract, “Methods” is incomplete and should include other important experiments performed, such as cell viability, apoptosis, cell cycle, and etc.

   According to the comment of reviewer, we have revised the Methods in the abstract (Paragraph 2, Page 1).

2. Please add Western blot findings for Caspase-3, MCL-1, Bcl-X1 in Figure 1e

   The indicated western blot findings were updated in Figure 1e. (Paragraph 1, Page 8)

3. Figure 1c revealed a significant reduction of CDK6 in SU-DHL-6 cell line after treatment with 6.25uM SHR2554. However, the reduction of CDK6 was not significant in figure 3b when SU-DHL-6 cell line was treated with 8uM SHR2554.

   In Figure 1C, we repeated these similar experiments for several times and confirmed that EZH2 inhibitor SHR2554 alone could reduce the expression of CDK4 and CDK6 in EZH2 mutant SU-DHL-6 cells. But in order to observe the synergistic effect of combination treatment more clearly, the different film exposure times were used in Figure 1C and Figure 3B. Thus, the CDK4 and CDK6 expressions were just look like slightly reduced by SHR2554 treatment in Figure 3B.

4. Some typos are noted. Please carefully proofread.

   According to the comment of reviewer, the careful proof reading was done to the whole article.